Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

A Different World: Metastatic Breast Cancer

October 25, 2015

By Cure Magazine

There are now more experimental options than ever: New treatments that target the immune system, like the one Blachowiak takes, enlist a patient’s immune cells to fight the cancer, and could be a game-changer for “triple-negative” breast cancer, one of the hardest to treat.

Marker may predict risk of breast cancer spreading to the brain

October 22, 2015

By University of Wisconsin-Madison

A UW-Madison scientist working with an international team of researchers has developed a new tumor marker test that may help predict whether breast cancer is likely to spread or metastasize to the brain, a deadly complication with survival typically measured only in months after diagnosis.University of Wisconsin-Madison

Blackwell Discusses Emerging HER2-Positive Breast Cancer Agents

October 20, 2015

By OncLive

Emerging therapies are advancing through the pipeline in HER2-positive breast cancer, potentially giving oncologists options beyond some of the current treatments, such as pertuzumab (Perjeta), trastuzumab (Herceptin), and ado-trastuzumab emtansine (T-DM1; Kadcyla).

Javier Cortés, MD, on the CLEOPATRA Trial

October 15, 2015

By Oncology Journal

One of the most amazing results from the CLEOPATRA study was the overall survival (OS) data.

The Next Promising Frontier of Precision Medicine: Metastatic Breast Cancer

October 15, 2015

By Marc Hulbert PhD

One of the most promising frontiers for precision medicine is research in metastatic breast cancer.

PANVAC plus docetaxel may have clinical benefit for metastatic breast cancer

October 9, 2015

By Healio HemOnc Today

The addition of a poxviral-based cancer vaccine, or PANVAC, to docetaxel may confer a clinical benefit for patients with metastatic breast cancer, according to the results of a randomized phase 2 study.

Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast ...

October 8, 2015

By FDA Today

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer

Breast cancer and mammograms: Study suggests ‘widespread overdiagnosis’

September 2, 2015

By The Washington Post

As expected, the researchers found that the number of breast cancer diagnoses rose with more aggressive screenings. The surprise: the number of deaths remained the same.

Is ER the new HER2 (which used to be the new ER)? Drs Lisa Carey and Eric Winer elaborate

September 2, 2015

By Neil Love, MD

To sort out what this development and others in the management of ER-positive breast cancer mean to daily patient care and clinical research I sat down with Drs Lisa Carey and Eric Winer, and this, the first of 2 programs developed from that conversation, provides an array of video highlights focused on palbo, other CDK inhibitors and the remarkable evolution of genomic assays in the selection of systemic therapy for patients with localized ER-positive, HER2-negative disease. The video comments are available with a quick click and are summarized below.

Combination PANVAC, Docetaxel May Provide Benefit in Breast Cancer

August 24, 2015

By Cancer Therapy Advisor

Results from an open-label phase 2 randomized clinical trial suggested that the combination of PANVAC and docetaxel in metastatic breast cancer may provide clinical benefit, according to an article published online ahead of print in JAMA Oncology.
 < 1 2 3 4 >  Last ›